Yellowbird Diagnostics Completes Dosing in First-in-Human Phase 1 Trial of NeuCaVis(TM)
Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Yellowbird Diagnostics Inc. today announced the successful completion of dosing and imaging in its first-in-human Phase 1 clinical trial of NeuCaVis™, a novel F18 PET radiotracer designed to image inflammation. Led by Dr. Benjamin Chow, the study enrolled twelve healthy volunteers, including six men and six women, at the Ottawa Heart Institute. The trial is evaluating the safety, tolerability, biodistribution, and dosimetry of NeuCaVis™,...
2026-06-22 7:51 AM EDT
Yellowbird Diagnostics Announces First Patients Dosed in Phase 1 Trial of NeuCavis(TM)
Ottawa, Ontario--(Newsfile Corp. - April 15, 2026) - Yellowbird Diagnostics Inc. today announced the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis™, a novel metabolic PET imaging agent designed to enable precise visualization of inflammation.
2026-04-15 7:15 AM EDT